Dengue virus neutralization is modulated by IgG antibody subclass and Fcγ receptor subtype  by Rodrigo, W.W. Shanaka I. et al.
Virology 394 (2009) 175–182
Contents lists available at ScienceDirect
Virology
j ourna l homepage: www.e lsev ie r.com/ locate /yv i roRapid Communication
Dengue virus neutralization is modulated by IgG antibody subclass
and Fcγ receptor subtype
W.W. Shanaka I. Rodrigo a, Olivia K.T. Block b, Christopher Lane c, Soila Sukupolvi-Petty d, Ana P. Goncalvez e,
Syd Johnson f, Michael S. Diamond d, Ching-Juh Lai e, Robert C. Rose b,c, Xia Jin b,c, Jacob J. Schlesinger c,⁎
a Department of Pathology and Laboratory Medicine, University of Rochester, Rochester, NY 14642, USA
b Department of Microbiology and Immunology, University of Rochester, Rochester, NY 14642, USA
c Department of Medicine, University of Rochester, Rochester, NY 14642, USA
d Departments of Medicine, Molecular Microbiology, Pathology and Immunology, Washington University, St. Louis, MO 63110, USA
e Laboratory of Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
f MacroGenics, Inc. Rockville, MD 20850, USA⁎ Corresponding author. Division of Infectious Disea
University of Rochester School of Medicine and Dentistr
Rochester, NY 14642, USA. Fax: +1 585 442 9328
E-mail address: jacob_schlesinger@urmc.rochester.e
0042-6822/$ – see front matter © 2009 Elsevier Inc. A
doi:10.1016/j.virol.2009.09.024a b s t r a c ta r t i c l e i n f oArticle history:
Received 3 August 2009
Returned to author for revision
1 September 2009
Accepted 16 September 2009
Available online 14 October 2009
Keywords:
Dengue virus
Virus neutralization
Humanized monoclonal antibody
Fc receptorSevere dengue virus (DENV) infection is epidemiologically linked to pre-existing anti-DENV antibodies
acquired by maternal transfer or primary infection. A possible explanation is that DENV immune complexes
evade neutralization by engaging Fcγ receptors (FcγR) on monocytes, natural targets for DENV in humans.
Using epitope-matched humanized monoclonal antibodies (mAbs) and stable FcγR-transfected CV-1 cells,
we found that DENV neutralization by IgG1, IgG3, and IgG4 mAbs was enhanced in high-afﬁnity FcγRIA
transfectants and diminished in low-afﬁnity FcγRIIA transfectants, whereas neutralization by IgG2 mAbs
(low-afﬁnity ligands for both FcγRs) was diminished equally. In FcγR-negative Vero cells, IgG3 mAbs
exhibited the strongest neutralizing activity and IgG2, the weakest. Our results demonstrate that DENV
neutralization is modulated by the Fc region in an IgG subclass manner, likely through effects on virion and
FcγR binding. Thus, the IgG antibody subclass proﬁle generated by DENV infection or vaccination may
independently inﬂuence the magnitude of the neutralizing response.
© 2009 Elsevier Inc. All rights reserved.Introduction
Current experimental evidence supports a multi-hit occupancy
model of ﬂavivirus neutralization where antibodies directed at a
virion envelope protein interfere with attachment or fusion if coating
levels are high enough (reviewed in: Pierson et al., 2008). This notion
also suggests an explanation for the paradox of enhanced ﬂavivirus
infection by neutralizing antibodies in Fcγ receptor (FcγR)-bearing
cells; at lower levels of antibody occupancy, which are sub-
neutralizing in nature, virus-immune IgG complexes can enhance
dengue virus (DENV) attachment by engaging FcγRs and infection of
monocyte/macrophages (Mo/Mϕ). This in vitro ﬁnding provides the
basis for a hypothesis of antibody-dependent enhanced infection
(ADE) to explain more severe infection in individuals with pre-
existing DENV antibodies acquired by maternal transfer or primary
infection (reviewed in: Halstead, 2003). DENVs exist as four
serologically distinct but antigenically related virus types (DEN1
through 4), which can cause sequential human infection. Homotypic
antibodies confer durable DENV serotype-speciﬁc immunity whereasses, Department of Medicine,
y, Box 689, 601 Elmwood Ave.,
du (J.J. Schlesinger).
ll rights reserved.cross-reactive neutralizing antibodies are generally weaker and less
protective, and presumably can more readily form DENV immune
complexes that remain infectious upon FcγR engagement.
FcγRs comprise a multi-gene family of type 1 integral membrane
glycoproteins (reviewed in: (Nimmerjahn and Ravetch, 2008)).
Among these, IgG receptors of two activation FcγR classes displayed
on DENV-permissive human Mo/Mϕ and dendritic cells (DCs) have
speciﬁcally been shown to modulate DENV immune complex
infectivity (Boonnak et al., 2008; Kou et al., 2008; Littaua, Kurane,
and Ennis, 1990; Mady et al., 1991; Rodrigo et al., 2006). The ﬁrst,
FcγRIA (CD64), has high afﬁnity for both monomeric and complexed
IgG and is found exclusively on antigen-presenting macrophages and
DCs. The second, FcγRIIA (CD32), exists in two allotypic forms (H/
R131) that preferentially bind multimeric IgG complexes with at least
100-fold lower afﬁnity than FcγRIA. FcγRIA acquires signaling
function by association with the common γ-chain subunit, whereas
the FcγRIIA ligand binding chain is intrinsically signaling-competent.
The DENV virion E protein ectodomain is comprised of three
domains (DI, DII, DIII), each of which is targeted by neutralizing
antibodies. However, the IgG subclass and antigenic distribution of
naturally stimulated neutralizing antibodies remains to be fully
elucidated and molecular dissection of DENV immune complex
interaction with FcγRs is just beginning. Here, we use epitope-
matched humanized mAb Fc variants to evaluate the effect of IgG
176 Rapid Communicationsubclass on DENV virion binding, and neutralization in African green
monkey kidney Vero and CV-1 cells which lack Fc receptors, and in
CV-1 cells which were stably transfected to express human FcγRIA or
FcγRIIA. Our results demonstrate that DENV neutralization is
modulated in an IgG subclass manner, possibly through independent
Fc effects on virion and FcγR binding.
Results
Functional human FcγRs displayed on DENV-permissive CV-1 cells
We evaluated DENV immune complex interactions with FcγRIA
and FcγRIIA transfected individually into Fc receptor-negative CV-1
cells, which like Vero cells are used in conventional DENV plaque
reduction neutralization (PRNT) assays. Coding sequences of human γ
chain and FcγRIA arranged in a bicistronic expression cassette to
ensure optimal and equivalent protein expression (Rodrigo et al.,
2006), and those of both human FcγRIIA allotypes were respectively
integrated into the identical single chromosomal site in CV-1/FRT
cells. A CV-1 empty vector-transfected cell line served as the FcγR-
negative CV-1 cell control. The three FcγR-expressing CV-1 cell lines
(Fig. 1A) displayed the respective FcγR type in comparable abundance
(∼300,000 FcγR molecules per cell) that was essentially unchanged
during continuous culture for ∼3 months.
IgG engagement by the FcγR transfectants was assessed by a
competition binding assay (Fig. 1B). The FcγRIA and FcγRIIA
transfectants efﬁciently bound (82%–97%) rabbit IgG opsonized
sheep red blood cells (SRBC) forming rosettes; control CV-1
transfectants did not bind SRBC. To verify predicted IgG complex
binding proﬁles among the FcγRs (Bruhns et al., 2009) we measured
the ability of human IgG myeloma protein aggregates of different
subclasses to inhibit SRBC rosette formation (Fig. 1B). IgG aggregates
exhibit properties of immune complexes and FcγR engagement by
these particular myeloma proteins has previously been measured
(Anderson and Abraham, 1980). Competition binding proﬁles among
the different FcγRs were mainly in agreement with those predicted
from a comprehensive reexamination of human FcγR binding
preferences (Bruhns et al., 2009); concordantly, pre-treatment with
human IgG1 and IgG3myeloma proteins almost completely abrogated
binding of opsonized SRBC by all three FcγR types, whereas inhibition
of rosette formation by IgG2 aggregates was mainly found in the
FcγRIIA-H131 transfectant (∼65%). In contrast, however, we found
that IgG2 aggregates bound to FcγRIA, albeit weakly (∼20% rosette
inhibition), but appeared not to bind to FcγRIIA-R131.
We next measured efﬁciencies of DENV1 and DENV2 plaque
formation among control and FcγR expressing CV-1 cell lines in the
absence of antibody and found them to be comparable (Fig. 1C).
Similarly, the amount of DENV2 released into infected cell culture
supernatants over a 72 h interval was similar among the four CV-1 cell
lines (data not shown).
Chimeric DENV mAbs with distinct human Fc regions
All IgG subclasses are represented in the antibody response to
human DENV infection and transferred maternally (Watanaveeradej
et al., 2003), but how IgG antibody subclass inﬂuences DENV
neutralization is incompletely understood. Chimeric DENV mAbs of
known epitope speciﬁcity with distinct human Fc domains offer novel
tools to address this question. Summarized in Table 1 are the
properties of three such epitope-matched DENV mAb panels
comprising different human IgG subclasses. The ﬁrst, mAb DV1-E50,
was originally generated as a mouse IgM after immunization with DIII
of DENV1 envelope protein. Its epitope maps to the A-strand of DIII
(residues K307 and K310) by cell surface display of DIII mutants on
yeast (S. Sukupolvi-Petty andM. Diamond, unpublished results). DV1-
E50 is DENV sub-complex speciﬁc, binding (weakly) to DENV2 andDENV3, but not to DENV4. The second, mAbWNV-E60 (mouse IgG2a),
was generated after immunization with West Nile virus (WNV). It is
ﬂavivirus cross-reactive and maps to amino acids within WNV DII
fusion loop (Oliphant et al., 2006). Recombinant Fc switch variants of
mAbs DV1-E50 and WNV-E60 incorporate a full-length heavy chain
constant region corresponding to each human IgG subclass. The third
chimeric mAb, 1A5, was generated from a chimpanzee that was
sequentially infected with all four DENV serotypes, and is directed at a
ﬂavivirus cross-reactive site on the DII fusion loop (Goncalvez et al.,
2004b). It incorporates a full-length human IgG1 heavy chain (1A5
WT). Notably, sub-neutralizing concentrations of mAb 1A5 WT
enhanced DENV4 replication in monkey primary blood monocytes
and DENV4 viremia in monkeys after passive transfer (Goncalvez et
al., 2007). Focused IgG2 or IgG4-speciﬁc amino acid residue substitu-
tions in the FcγR-binding motif of 1A5 WT produced mutants with
FcγR binding properties of IgG2 (1A5 ΔB) and IgG4 (1A5 ΔA); a 9-
amino acid deletion at the 1A5 WT Fc N terminus (1A5 ΔD)
completely abrogated FcγR attachment (Goncalvez et al., 2007).
mAb Fc variants differentially neutralize DENV in Fc receptor-negative
Vero cells and bind virions in an ELISA
To evaluate a possible Fc region effect on neutralization indepen-
dent of FcγR engagement, we generated DENV neutralization dose
response curves with each chimeric mAb in Vero cells, which lack
expression of Fc receptors (Table 1, Fig. 2). We observed divergent
PRNT50 titers and neutralization dose responses amongmAb DV1-E50
andmAbWNV-E60 full-length Fc switch variants; the IgG3 versions of
both mAbs exhibited the most potent neutralizing activity against
DENV1 or DENV2, and the IgG2 versions were the least potent
(Fig. 2A–C). Because several recent studies suggested that the Fc region
of a given IgG subclass could modulate antigen speciﬁcity and afﬁnity
of anti-cryptococcal antibodies (Dam et al., 2008; Torres and
Casadevall, 2008; Torres et al., 2007), we reasoned that at least part
of the altered neutralization proﬁles by the IgG switch variants could
be a function of differential avidity for DENV particles. To test this, we
measured whether antibody subclasses of a given mAb differentially
bound intact DENV virions in a capture ELISA (Fig 2). Whereas
differences in neutralization potency were substantial among the full-
length IgG variants (up to ∼10-fold), their differential effects on virion
binding were relatively small (∼2-fold, or less). Nevertheless, the
neutralization and virion binding assay proﬁles appeared roughly
concordant particularly with respect to differences between the full-
length IgG3 and IgG2 variants. Among mAb DV1-E50 Fc variants, the
IgG3 version, which exhibited the highest neutralizing potency, also
bound more avidly than did the much more weakly neutralizing IgG2
version (Table 1, Fig. 2A). However, divergent binding avidities
comparable to those of the IgG3 and IgG2 versions, were also observed
between mAb DV1-E50 IgG1 and IgG4, respectively although these
mAbs exhibited similar intermediate neutralizing potencies, With
mAb WNV-E60, both IgG3 and IgG4 versions bound DENV1 (Fig. 2B)
and DENV2 (Fig. 2C) comparably and more strongly than did the IgG1
and IgG2 versions. Notably, we found no differences in neutralization
or virion binding proﬁles among the mAb 1A5 Fc variants, which
contain focal mutations that alter IgG subclass speciﬁcity (Fig. 2D).
Thus, our ﬁndings agree with the studies involving cryptococcal
antibodies and suggest that the constant region of the heavy chain of
IgG can alter antigen speciﬁcity, which affects the neutralizing
potential of mAbs against DENV in the absence of FcγR interactions.
FcγR class differentially modulates DENV neutralization by mAb
Fc variants
We next compared DENV neutralization potencies among the
mAbs in FcγR-transfected and control CV-1 cell lines (Fig. 3). Overall,
DENV neutralization by IgG1, IgG3, and IgG4 mAbs was enhanced in
Fig. 1. CV-1 cell lines display functional human FcγRIA/γ and FcγRIIA. (A) FcγR expression. PE-labeled monoclonal antibodies against FcγRIA (CD64) or FcγRIIA (CD32) were used with
corresponding labeled isotype controls to verify FcγR expression by ﬂow cytometry. Human macrophage-like THP-1 cells which express FcγRIA and FcγRIIA (Fleit and Kobasiuk, 1991),
served as a staining control. Results are representative of at least 6 independent determinations performed during an approximately 3-month period of continuous culture of the FcγR
transfectants. (B) Competition-inhibition by aggregated IgG myeloma proteins. Pre-treatment of FcγRIA and FcγRIIA transfectants with heat-aggregated human IgG1 and IgG3myeloma
proteins inhibited (≥90%) rosette formation by rabbit IgG-sensitized sheep red blood cells (SRBC). IgG2 myeloma protein preferentially bound to FcγRIIA-H (∼60% rosette inhibition).
Mean values of triplicate samples and S.E.M. are plotted. Data are representative of four similar experiments. (C) Efﬁciency of DENV plaque formation in CV-1 transfectants. CV-1
transfectants were infected with serial two-fold (25 to 200) PFU of DENV1 or DENV2. Plaques were detected by indirect immunostaining with a broad DENV serogroup-reactive NS1-
speciﬁcmonoclonal antibody (9A9).MeanvaluesandS.E.M. are indicated for eachcondition.Differences inplaquenumbersover the range of inputDENVPFUwerenot signiﬁcant (PN0.92,
one-way ANOVA). Graphs were generated from an experiment performed in triplicate for both DENV serotypes and are representative of three similar experiments.
177Rapid Communicationhigh-afﬁnity FcγRIA transfectants and diminished in low-afﬁnity
FcγRIIA transfectants compared to neutralizing activity in control CV-
1 cells. Notably, IgG2 mAbs, which are low-afﬁnity ligands for bothFcγRIA and FcγRIIA, exhibited comparably diminished neutralization
potency in each FcγR type (Figs. 3A–C). IgG2 DENV immune
complexes, which are expected to bind to both FcγRIIA allotypes
Table 1
Humanized monoclonal antibodies: Antigenic, neutralization, and virion binding
properties.
Chimeric mAb mAb Isotype PRNT50 (μg/ml)a Virion binding
(Kd-app, nM)b
Mouse–human
DV1-E50 (D-III)c DENV1 DENV2 DENV1 DENV2
DV1-E50-1 IgG1 0.18 – 11.9 –
DV1-E50-2 IgG2 0.95 – 19.0 –
DV1-E50-3 IgG3 0.02 – 8.1 –
DV1-E50-4 IgG4 0.10 – 15.4 –
WNV-E60 (D-II)
WNV-E60-1 IgG1 0.39 0.03 20.8 9.1
WNV-E60-2 IgG2 1.52 0.30 19.4 8.6
WNV-E60-3 IgG3 0.17 0.01 7.7 7.2
WNV-E60-4 IgG4 0.38 0.04 9.3 7.2
Chimpanzee–human
1A5 (D-II)
1A5 WT IgG1 – 0.84 – 21.0
1A5 ΔA IgG4 – 0.89 – 18.4
1A5 ΔB IgG2 – 0.83 – 46.7
1A5 ΔD IgG9Xd – 0.82 – 22.5
a 50% Plaque reduction neutralization (PRNT50) end-point titers in Vero cells
calculated by probit analysis.
b Values represent the apparent Kd (Kd-app) calculated for the mAb concentration
that produced 50% of maximum virion binding determined by ELISA.
c DENV envelope E domain (D) speciﬁcity.
d 9-amino acid Fc deletion into the 1A5 Fc CH2 domain.
178 Rapid Communication(Bruhns et al., 2009), were neutralized with similar efﬁciency in
FcγRIIA-H131 and FcγRIIA-R131 transfectants.
A speciﬁc effect of FcγR engagement on neutralization by the mAb
IgG subclass variants is highlighted by the neutralization proﬁle of
mAb 1A5 ΔD (which is not bound by FcγR): neutralization was
identical among the FcγR-expressing and control CV-1 cells (Fig. 3D).
Thus, transfectants are comparably susceptible to DENV infection and
neutralization in the presence of an antibody that cannot engage
FcγRs.
The striking reduction in DV1-E50 andWNV-E60 IgG2 neutralizing
potency in FcγRIA/γ transfectants compared to that of the other IgG
subclass versions was surprising. Since FcγRIA has relatively little
afﬁnity for IgG2 (Fig. 1B), we questioned whether the neutralization
disparity involved engagement of this receptor at all. Shown in Fig. 3E
are results of a competition experiment designed to address this
possibility. We measured neutralization of DENV1 by mAb DV1-E50
IgG2 in the CV-1 transfectants in the presence of graded amounts of
human IgG1, IgG2, or IgG3 myeloma proteins using human serum
albumin (HSA) as an irrelevant protein control. Treatment with
increasing amounts of high-afﬁnity IgG1 and IgG3 myeloma proteins,
which bind avidly to FcγRIA, progressively increased DV1-E50 IgG2
neutralizing potency in a dose-dependent manner that approached
but did not exceed that observed in control CV-1 cells. No such effect
was observed in FcγRIIA-expressing CV-1 cells or in either FcγR cell
type by treatment with human IgG2 myeloma or control HSA. These
results suggest that the DENV IgG2 immune complexes bind FcγRIA
and that neutralization is decreased by FcγRIA/γ engagement, an
effect opposite to that observed with DENV complexed by other IgG
antibody subclasses.
Discussion
In this study, we evaluated how engagement of human IgG
antibody Fc and FcγRs modulates DENV neutralization. To do so, we
used epitope-matchedmAb switch variants corresponding to each IgG
subclass and stable transfectants that display functional FcγR types
individually, and in comparable abundance. Several conclusions
emerge from our ﬁndings. First, FcγRIA/γ and FcγRIIA modulate
DENV neutralization in an antibody subclass-dependent manner.
Neutralization potency was proportional to FcγR-DENV immunecomplex binding avidity such that overall, neutralization by IgG1,
IgG3, and IgG4 mAbs was enhanced in high-afﬁnity FcγRIA transfec-
tants and markedly diminished in low-afﬁnity FcγRIIA transfectants.
Neutralization by IgG2 mAbs (low-afﬁnity ligands for both FcγR
types) was diminished equally. Because depressed IgG2 antibody-
mediated DENV neutralization in FcγRIA/γ-expressing cells was
reversed by FcγRIA blockade (Fig. 3E), we speculate that FcγRIA/γ
binding and/or signaling contributes to neutralization through an as
yet undetermined mechanism.
Our ﬁnding that DENV neutralization was enhanced by high-
afﬁnity FcγRIA/γ engagement is consistent with a recent study of HIV
immune complex infectivity in FcγR transfectants (Perez et al., 2009).
HIV neutralization by IgG1 or IgG3 mAbs directed to gp41 was
enhanced in FcγRIA/γ-expressing TZM-bl cells. In apparent contrast
to the present results with DENV, the FcγRIA/γ neutralization
enhancing effect with HIV was highly epitope-speciﬁc and neutral-
ization potency among the HIV mAbs was generally the same in
control and FcγRIIA-expressing cells. However, a single mAb and HIV
strain combination exhibited somewhat reduced virus neutralization
in FcγRIIA transfectants; low-afﬁnity IgG2 immune complexes were
not studied.
Our second key ﬁnding emerges from neutralization measure-
ments performed in cells lacking FcγRs. Here, IgG3 variants of mAbs
DV1-E50 and WNV-E60 neutralized DENVs in Vero cells more
efﬁciently than did other IgG subclasses, with IgG2 variants being
the least potent. The superiority of human IgG3 antibody neutral-
izing potency has been observed with other viruses, most notably
HIV (Cavacini et al., 1995; Liu et al., 2003; Scharf et al., 2001) and
our results suggest that IgG3 antibodies may preferentially
neutralize DENVs as well. This property has been explained by an
inherently greater ﬂexibility of IgG3 and evidence of an allosteric
effect of the IgG heavy-chain constant region on Fab afﬁnity and
speciﬁcity (reviewed in (Torres and Casadevall, 2008)). The link
between neutralization potency in Vero cells and virion binding
avidity among mAb DV1-E50 and WNV-E60 switch variants
appeared imperfect as no discernable difference in neutralizing
potency was observed among the mAb 1A5 variants in Vero cells.
However, the mAbs DV1-E50 and WNV-E60 incorporate complete
human heavy chain constant regions, whereas the mAb 1A5
variants were prepared by limited Fc region amino acid substitu-
tions known to confer IgG subclass-speciﬁc FcγR binding (Armour
et al., 1999; Armour et al., 2003; Goncalvez et al., 2007), but
perhaps not alter virion binding. It is worthwhile also considering
that discrepancies between virion binding avidity and neutralization
potency might reﬂect other properties of a particular neutralizing
antibody such as whether it acts by blocking virion attachment or
fusion.
Taken together, the data suggest that IgG neutralization potency is
modulated by a combined Fc effect on virion avidity of binding (e.g.
hinge ﬂexibility) and FcγR preference. Whether these Fc functions act
independently to inﬂuence DENV neutralization and what other Fc
effects on DENV infectivity might be operating, will be addressed in
future experiments.
Finally, our data with infectious DENV immune complexes are
consistent with the notion of “two-point” attachment of antibody-
coated DENV that involves both the FcγR and a putative virus
receptor. Ligand-clustered Fc receptors, including FcγRIIA (Kwiat-
kowska and Sobota, 2001), concentrate in cell membrane regions,
(e.g. lipid rafts) rich in signaling molecules and potential virus
receptor engagement sites. We speculate that the relatively weak
DENV immune complex binding to FcγRIIA (independent of the IgG
subclass) and fast off-rate (Maenaka et al., 2001) lead to a virus
receptor-mediated entry pathway that favors virion infectivity,
whereas DENV immune complexes comprised of IgG subclasses
that are relatively tightly bound to FcγRIA/γ (i.e. IgG1, IgG3, and
IgG4) are co-internalized upon cross-linking, and are then directed
Fig. 2. Differential binding and neutralization by anti-DENV humanized IgG mAbs. DENV virion binding and neutralization by puriﬁed chimeric mouse-human mAb variants (DV1-
E50; WNV-E60) or chimpanzee-human mAb variants (1A5 WT, 1A5 ΔA, 1A5 ΔB). mAb DV1-E50 or WNV-E60 variants incorporated a full-length Fc region corresponding to each
human IgG subclass whereas mAb 1A5 variants contained focused amino acid substitutions in the 1A5 WT IgG1 Fc portion that conferred IgG2 (1A5 ΔB) or IgG4 (1A5 ΔA) ligand
properties for FcγR binding; a 9-amino acid deletion (1A5 ΔD) abrogated FcγR binding entirely. DENV neutralization dose-response and virion binding curves were generated by
parallel plaque reduction neutralization assay in Fc receptor-negative Vero cells and virion-capture ELISA assay, respectively. (A) mAb DV1-E50 IgG subclass variants titrated against
DENV1. (B, C) mAb WNV-E60 IgG variants titrated against DENV1 and DENV2, respectively. (D) mAb 1A5 IgG variants titrated against DENV2. Plaques were detected by indirect
immunostaining with a DENV NS1-speciﬁc monoclonal antibody (9A9) and neutralization dose-response curves were generated using GraphpadPrism5 software. Mean values and
S.E.M. of triplicate ELISA determinations and duplicate or triplicate neutralization determinations are plotted. ELISA and neutralization results are representative of at least two
similar studies.
179Rapid Communicationto a virus-destructive intracellular pathway. DENV immune com-
plexes comprised of IgG2 antibody are exceptional as they weakly
bind FcγRIA and thus, likely utilize the same internalization
pathway available to FcγRIIA-bound DENV. Failure of low-afﬁnity
IgG2-DENV immune complexes to efﬁciently cross-link FcγRIA/γand trigger signaling may also contribute to the divergent
neutralization effect. Since IgG1 is more abundant than IgG2 in
human serum, it seems possible that irrelevant IgG1 antibodies
could modulate the FcγRIA inﬂuence on IgG2 DENV neutralizing
antibodies in vivo.
180 Rapid Communication
181Rapid CommunicationIn conclusion, our ﬁndings point to a high level of complexity in
the interplay between antibody-coated virion, FcγR, and virus
receptor, one in which antibody isotype and FcγR independently
and interdependently modulate functional outcome. The mechanisms
involved are likely shared among disparate viruses, but are also likely
to involve aspects that are unique to a particular virus and host cell
type.
Materials and methods
Cells and viruses
Vero cells and C6/36 Aedes albopictus mosquito cells were grown
in minimum essential medium; THP-1 cells were grown in RPMI 1640
medium. All media were supplemented with heat-inactivated (1 h at
56 °C) fetal bovine serum (HyClone, Logan, UT). DENV1 (16007) and
DENV2 (16681), (Dr. Richard Kinney CDC, Ft. Collins, CO) were
propagated from reference stock by a single passage in mosquito cells
and titered by plaque assay in Vero cells.
Preparation of FcγR-expressing CV-1 cells
A bicistronic expression cassette in a pcDNA5/FRT backbone
containing the human γ chain and FcγRIA coding sequences has been
previously described (Rodrigo et al., 2006). Human FcγRIIA (H131 and
R131 allotypes) genes were individually generated in the same vector.
Construct sequences were veriﬁed by DNA sequence analysis. A ﬂp
recombinase-mediated integration system (“Flp-In System,” Invitro-
gen Corp., Carlsbad, CA) was used to engineer the respective FcγR or a
control empty vector into CV-1 cells bearing a single, ﬁxed
chromosomal recombination “FRT” site (CV-1/FRT) following the
manufacturer's instructions. Gene integration was veriﬁed by PCR
ampliﬁcation and DNA sequencing.
Cell surface FcγRIA and FcγRIIA were detected and quantiﬁed as
previously described (Rodrigo et al., 2006). Brieﬂy, THP-1 cells or
control and CV-1/FcγR transfectants were stained with R-Phycoery-
thrin (PE)-conjugated IgG1 mAbs against human FcγRIA (CD64 mAb
10.1; eBioscences, San Diego, CA) or FcγRIIA (CD32 H/R131, mAb
AT10, Serotec, Raleigh, NC) using a PE-labeled mouse IgG1 isotype
control from the corresponding manufacturer. Stained cells were
analyzed by FACSCalibur using CellQuest software (BD Immunocyto-
metry Systems, Franklin Lakes, NJ). The number of FcγRIA or FcγRIIA
molecules expressed on the surface of the CV-1 transfectants was
determined by a quantitative immunoﬂuorescence method that
employed standardized QuantiBRITE-PE beads (BD Pharmingen, San
Jose, CA).
IgG subclass binding speciﬁcity of FcγR-expressing CV-1 cells
IgG opsonized sheep red blood cells (SRBC) binding to FcγR
transfectants was measured as previously described (Rodrigo et al.,
2006). For competition binding assays, CV-1 transfectant suspensions
were treatedwith heat-aggregated puriﬁed human IgG1, IgG2, or IgG3
myeloma proteins (Dr. Clark Anderson, OSU, Columbus OH) or human
serum albumin (Anderson and Abraham, 1980) followed by mixing
with opsonized SRBC and counting. The percentage of inhibition of
rosette formation (%I) was calculated by: %I=(% rosettes in untreatedFig. 3. Neutralization of DENV by humanized IgG mAbs in FcγR transfectants. DENV (200 PF
used to generate neutralization dose-response curves in control and FcγRIA/γ or FcγRIIA sta
WNV-E60 variants titrated against DENV1. (C) mAb 1A5 WT (IgG1), 1A5 ΔB (IgG2), 1A5 ΔA
FcγRIIA-expressing CV-1 cells were treated with a mixture of DENV1 immune complex
concentrations (0.01 to 10 μg/ml) of puriﬁed human IgG1, IgG2, IgG3 myeloma proteins or c
was blocked by the high-afﬁnity IgG1 and IgG3 myeloma proteins only. Plaques were detec
Mean values and S.E.M. of triplicate infections are plotted. Results are representative of at lcells)−(% rosetting IgG myeloma protein-treated cells)/(% rosetting
in untreated cells)×100.
Chimeric mouse-human and chimpanzee-human DENV mAbs
Properties of humanized mouse or chimpanzee anti-DENV mAbs
used to prepare DENV immune complexes are summarized in Table 1.
Construction and characteristics of full-length humanized chimpan-
zee IgG mAb 1A5 variants have been previously described (Goncalvez
et al., 2007; Goncalvez et al., 2004a). Chimeric mouse-human mAbs
with human heavy chains were generated as follows: brieﬂy, DV1 E50
(DENV subcomplex-speciﬁc) andWNV E60 (ﬂavivirus cross-reactive)
heavy and light chain RNA were isolated from hybridoma cells after
guanidinium thiocyanate and phenol-chloroform extraction, and
converted to cDNA by reverse transcription. The VH and VL segments
were ampliﬁed by PCR using the 5′ RACE system as described
(Oliphant et al., 2005). The RACE products were inserted into the
plasmid pCR2.1-TOPO using the TopoTA kit (Invitrogen). The resulting
plasmids were then subjected to DNA sequencing to determine the
VH and VL sequences for DV1-E50 and WNV-E60. The cDNA
sequences were transcribed and the predicted amino acid sequence
determined. From these sequences the framework (FR) and CDR
regions were identiﬁed as deﬁned by Kabat et al. (1991). The mouse
VH was joined to individual human C-γ constant regions and an Ig
leader sequence, and inserted into pCI-neo for mammalian expres-
sion. The mouse VL was joined to a human Cκ segment and an Ig
leader sequence and also cloned into pCI-neo for mammalian
expression of chimeric DV1-E50 or WNV-E60. The resulting plasmids
were co-transfected into human 293T cells using Lipofectamine-2000
and the chimerized antibodies with different human heavy chains
were recovered from the resulting conditioned medium and puriﬁed
by protein A or G, and size exclusion chromatography. Human
chimeric or full-length humanized chimpanzee mAbs were used in
afﬁnity-puriﬁed form in PBS. Puriﬁed antibody concentrations were
determined using a Bio-RAD DC protein assay kit (Bio-RAD Labora-
tories, Hercules, CA) and by UV spectrophotometry. Puriﬁed human
IgG (Sigma Aldrich, St. Louis, MO) was used as a standard.
DENV mAb virion binding assay
A previously described enzyme-linked immunosorbent assay
(ELISA) method was modiﬁed to measure humanized mAb binding
to DENV virion (Goncalvez et al., 2004b). Brieﬂy, DENV1 or DENV2
virions (1×105 PFU/well) from mosquito cell cultures were bound to
C-bottom ELISA plates pre-coated with an afﬁnity-puriﬁed ﬂavivirus
cross-reactive mAb (7E1) prepared against DENV2 (J. J. Schlesinger,
unpublished). mAb binding curves were generated with GraphPad
Prism5 software from triplicate wells stained with an alkaline
phosphatase-conjugated goat anti-human IgG antibody (Southern
Biotechnology Associates, Inc., Birmingham, AL).
Measurement of DENV neutralization by immunofocus plaque reduction
assay
FBS used in the neutralization assays was heat-inactivated at
56 °C for 1 h. Pre-formed DENV immune complexes were prepared
by incubating 200 plaque forming units (PFU) of DENV withU) was incubated with graded concentrations of puriﬁed mAbs and the mixtures were
bly transfected CV-1 cells. (A) mAb DV1-E50 variants titrated against DENV1. (B) mAb
(IgG4) titrated against DENV2. (D) mAb 1A5 ΔD titrated against DENV2. (E) FcγRIA- or
es formed with DENV1 (200 PFU) and mAb DV1-E50 IgG2 (1 μg/ml), and graded
ontrol human serum albumin (HSA). FcγRIA but not FcγRIIA-modulated neutralization
ted by indirect immunostaining with a DENV NS1-speciﬁc monoclonal antibody (9A9).
east three (A–D) or two (E) similar experiments.
182 Rapid Communicationspeciﬁed antibody concentrations for 60 min at 37 °C. DENV in free
form or as immune complexes were adsorbed (200 μl per well) to
cell monolayers (2×105 cells per well) in 24-well polystyrene
cluster plates by incubation for 90 min at 37 °C followed by
aspiration of supernatant and overlaying with 0.6% agarose (SeaKem
GTG, FMC BioProducts, Rockland, Me) in MEM with 10% FBS. For
competition experiments, puriﬁed control HSA or IgG myeloma
proteins were mixed with DENV immune complexes before addition
to established CV-1 cell monolayers. After overnight incubation at
37 °C the newly established cell monolayers were washed with PBS
and overlaid with agarose. DENV plaques were immunostained and
counted as previously described (Rodrigo et al., 2006). GraphPad
Prism5 software was used to generate neutralization dose-response
curves by sigmoidal curve-ﬁt and to calculate 50% plaque reduction
neutralization test (PRNT50) end-point titers by probit analysis
(Russell et al., 1967).
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